Inhibikase Therapeutics Stock Today
| IKT Stock | USD 2.01 0.03 1.52% |
Performance8 of 100
| Odds Of DistressLess than 45
|
Inhibikase Therapeutics is selling for under 2.01 as of the 22nd of November 2024; that is 1.52 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.75. Inhibikase Therapeutics has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Inhibikase Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of December 2020 | Category Healthcare | Classification Health Care |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company has 67.19 M outstanding shares of which 187.95 K shares are currently shorted by investors with about 0.17 days to cover. More on Inhibikase Therapeutics
Moving against Inhibikase Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Inhibikase Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Milton Werner | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsInhibikase Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inhibikase Therapeutics' financial leverage. It provides some insight into what part of Inhibikase Therapeutics' total assets is financed by creditors.
| |||||
Inhibikase Therapeutics (IKT) is traded on NASDAQ Exchange in USA. It is located in 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 and employs 8 people. Inhibikase Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 135.06 M. Inhibikase Therapeutics runs under Biotechnology sector within Health Care industry. The entity has 67.19 M outstanding shares of which 187.95 K shares are currently shorted by investors with about 0.17 days to cover.
Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28.
Check Inhibikase Therapeutics Probability Of Bankruptcy
Ownership AllocationInhibikase Therapeutics has a total of 67.19 Million outstanding shares. Inhibikase Therapeutics retains 10.46 (percent) of its outstanding shares held by insiders and 11.62 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Inhibikase Ownership Details
Inhibikase Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-06-30 | 42.0 | |
| Susquehanna International Group, Llp | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | |
| Redmond Asset Management, Llc | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-06-30 | 589.6 K | |
| Blair William & Co | 2024-06-30 | 116.1 K | |
| Citadel Advisors Llc | 2024-06-30 | 37.9 K | |
| Geode Capital Management, Llc | 2024-06-30 | 37.3 K | |
| Renaissance Technologies Corp | 2024-09-30 | 19.9 K | |
| Vanguard Group Inc | 2024-09-30 | 16.7 K |
Inhibikase Therapeutics Historical Income Statement
Inhibikase Stock Against Markets
Inhibikase Therapeutics Corporate Management
| Roger Rush | Head Research | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Surendra Singh | Manufacturing Chemistry | Profile | |
| Dan Williams | Controller | Profile |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.